Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3476336 | 0.89 | TACR1 (0.46) | TACR1 | |
| SCHEMBL3177591 | 0.84 | TACR1 (0.67) | TACR1 | |
| SCHEMBL4991726 | 0.83 | TACR1 (0.44) | TACR1 | |
| SCHEMBL3175433 | 0.83 | TACR1 (0.44) | TACR1 | |
| SCHEMBL4991723 | 0.82 | TACR1 (0.45) | TACR1 | |
| SCHEMBL3477649 | 0.80 | TACR1 (0.43) | TACR1 | |
| SCHEMBL1276300 | 0.79 | TACR1 (0.71) | TACR1 | |
| SCHEMBL5216191 | 0.79 | TACR1 (0.71) | TACR1 | |
| SCHEMBL5216199 | 0.79 | TACR1 (0.71) | TACR1 | |
| SCHEMBL3187855 | 0.78 | TACR1 (0.48) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683068-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7645790-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090054462-A1 | Hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
| US-20080280966-A1 | Hydroisoindoline Tachykinin Receptor Antagonists | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2008-11-13 | — | — | US | disclosed |
| US-7345083-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1711465-B1 | HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070161695-A1 | Hydroisoindoline tachykinin receptor antagonists | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2007-07-12 | — | — | US | disclosed |
| US-7217731-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050165083-A1 | Hydroisoindoline tachykinin receptor antagonists | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054462-A1 | Hydroisoindoline tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885 |
| US-20050165083-A1 | Hydroisoindoline tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885 |
| US-20070161695-A1 | Hydroisoindoline tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885 |
| US-20080280966-A1 | Hydroisoindoline Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.